Alkermes has a huge opportunity to expand its label to include pediatric patients with Schizophrenia and bipolar I disorder.

Tokyo, Japan and Cambridge, UK, 2 May 2025 - Nxera Pharma ("the Company” or "Nxera”; TSE: 4565) provides an update on ...

which met its primary endpoint for the once-daily 20 mg dose (as reported in August 2024). The Phase 3 study is a global double-blind, placebo-controlled trial evaluating NBI-’568 in adults with ...

Orexin is a molecule that promotes wakefulness ... compared to the placebo. A higher dose (20 mg, typically prescribed for insomnia) also lowered a particular form of tau protein, phosphorylated ...

Chronic insomnia is not just one bad night of sleep it’s a disorder that can wreak havoc on all aspects of life. For Miranda, ...

Read full article: Police looking for driver who hit, left man for dead in SW Houston Read full article: Save big on spring essentials with these Insider Deals 6-Piece Bamboo-Blend Comfort Luxury ...